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Abstract  
 
Background: Hurthle cell neoplasms (HCN) are considered a variant of follicular thyroid 
neoplasms, and accounts for 3-10% of neoplasms of the thyroid gland. They include Hurthle 
cell adenomas (HCA) and carcinomas (HCC). Differentiating HCA from HCC preoperatively 
is currently not possible. We retrospectively searched for demographic and histopathological 
factors which can be used to predict the risk of malignancy in HCN.  
Aim: To determine the prevalence of HCC and its demographic factors and histopathological 
features that can be used to predict the risk of malignancy in HCN.   
Methods: Records of all patients who underwent thyroidectomy at Academic Hospitals 
associated with University of the Witwatersrand from January 2001 to October 2015 were 
reviewed. Patients’ demographic data and the final histology of HCN were further analyzed 
including pre-operative fine needle aspiration cytology (FNAC) results. Data collected 
included patients’ demographic, final histology, tumor size and preoperative FNAC result. 
Data was entered into Excel Spreadsheet and analyzed using STATICA 13.1 program.  
Results: At total of 2641 records of thyroidectomies were found of which 25.6% (676/2641) 
were for thyroid neoplasms. Only 15.8% (107/676) of the neoplasms were HCNs and 25.2% 
(27/107) of HCNs were HCCs. Hurthle cell carcinoma made up 5.6% (27/481) of thyroid 
carcinomas. 70.4% (19/27) of HCCs were incidentally found following thyroidectomy for 
multinodular goiter (MNG). The mean tumor size was significantly greater for carcinomas 
than for adenomas (4.9 cm vs. 3.5 cm; p = 0.016). The risk of malignancy increased from 
11.1% when the size was less or equal to 1cm, through 33.3% for size of 1-4cm to 51.8% 
when the size was greater than 4cm in diameter. 
A total of 58 FNACs results of 107 HCNs were available for further analysis. Thirty one 
(53.4%: 31/58) of FNAC results were suspicious for HCN (Bethesda IV), seven (12.1%: 
7/58) suspicious of papillary carcinoma (Bethesda V) and eight (13.8%: 8/58) were reported 
as benign (Bethesda II). Around 10.3% (6/58) were non-diagnostic (Bethesda I) whereas 
8.6% (5/58) were reported as atypia of unknown significance (Bethesda III). Both HCA and 
HCC were more prevalent in females, 88.7% (71/80) and 77.8% (21/27); respectively. The 
mean age of the patients who had HCA and HCC in years was 52.3+/- 15.6 SD and 55.0 +/- 
15.0 SD, respectively.  
v 
 
Conclusion: Majority of HCCs are diagnosed following thyroidectomy for benign disease.  
Close to a quarter of HCNs are malignant and the risk of malignancy increases with size. Age 
and gender are not useful to predict malignancy in HCNs. We recommend total 
thyroidectomy for thyroid nodule greater than 4cm in diameter if FNAC result is suggestive 
of HCN as the risk of malignancy is above 50%.  
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CHAPTER ONE 
 
1.1. INTRODUCTION   
 
Hurthle cells (HC) are commonly reported on fine-needle aspiration cytology (FNAC) from 
thyroid nodules 
[1]
. Report of Hurthle cells or Hurthle cell changes in cytology result often 
lead to anxiety to the surgical team due to controversies associated with diagnosis, 
management and prognosis of Hurthle cell carcinoma (HCC) 
[1]
 
Before 1991, all Hurthle cell neoplasms were thought to have malignant potential and were 
therefore subjected to total thyroidectomy 
[2]
. The above was due to inability of thyroid 
FNAC to distinguish Hurthle cell adenoma (HCA) from HCC. Similar to follicular carcinoma 
(FC), diagnosis of HCC is only made if there is evidence of vascular and/or capsular invasion 
which is not possible to confirm on cytology specimen 
[1-3]
. Frozen section is not reliable 
either in the diagnostic work-up of HCN. Similarly, molecular analysis and Ki67 index 
evaluation of FNAC specimen are not helpful 
[1]
. Total thyroidectomy is sometimes preferred 
and recommended because HCC is more aggressive as compared to other differentiated 
cancers of the thyroid of follicular cell origin. Furthermore, HCC has higher propensity for 
multifocality and distant metastasis.   
Diagnostic work-up of a patient presenting with a thyroid nodule include history taking 
emphasizing on patient’s complaints, family history and environmental factors. Male gender, 
extremes of age, previous neck irradiation and family history, if positive should be of 
concern.  
 
1.2. BACKGROUND TO THE RESEARCH PROBLEM 
 
Thyroid carcinoma is the most common endocrine cancer, accounting about 3% of newly 
diagnosed cancers annually 
[3, 4]
. The incidence has been rising attributed to increase usage of 
screening tools and in part due to environmental factors which have led to surge of these 
cancers 
[5]
. Thyroid carcinoma is more common in women than men. The average age range 
from 20-85 years but any age group can be affected 
[6]
. Generally, thyroid malignancies are 
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broadly divided into primary and secondary cancers. Primary neoplasms are further 
subdivided into epithelial and non-epithelial neoplasms. Epithelial carcinomas include 
follicular and parafollicular C cells derived cancers. These are papillary, follicular and 
Hurthle cell carcinoma, anaplastic and medullary.  
Hurthle cell carcinoma is a relatively rare thyroid neoplasm, only consists of 5%  of all 
differentiated thyroid carcinoma 
[7]
. Hurthle cell neoplasm is considered as a variant of 
follicular thyroid neoplasm, but many authors think they are separate entities 
[8, 9]
. Therefore, 
handful institutions have accumulated more experiences on the diagnosis and management of 
HCN. Many controversies exist regarding the diagnosis, management and prognosis of HCC
 
[1]
. After a literature search, we could not find a study has been done in Southern Africa, 
regarding HCN.  The researchers carry out a retrospective analysis of histopathological and 
FNAC reports to determine prevalence HCN and if there clinicopathological factors that can 
be used to predict malignancy in HCN.  
 
1.3. STATEMENT OF THE RESEARCH PROBLEM 
 
Until not long time ago, patients with HCN where all subjected to total thyroidectomy 
leading to unnecessary complications. It was because all HCNs were having malignant 
potential.  Until recently, patients who were suspected to be having HCN on FNAC are pre-
operatively risk stratified into low and high risk groups. Patients with low risk potential were 
managed with lobectomy only unless the subsequent histology showed widely invasive HCC 
[10]
.Clinicopathological factors that are used to predict risk of malignancy among HCN are; 
older age, male gender and size of tumor more than 4cm in diameter. The researchers try to 
look for these risk stratifying clinical and histopathological factors in patients seen and 
operated at the university teaching hospitals.  
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1.4. AIM AND OBJECTIVES OF THE STUDY 
 
1.4.1: Study aim 
 
To determine the prevalence of HCC and its demographic factors and histopathological 
features that can be used to predict the risk of malignancy in HCN.   
 
1.4.2: Study objectives 
 
i. To determine the demographic and histopathological findings in patients who had HCN. 
ii. To determine what proportion of patients who had thyroidectomy for HCN were on 
histology confirmed to be having HCC. 
iii. To determine if fine needle aspiration cytology is able to distinguish HCA from HCC. 
iv. To determine if there are factors which are predictive of malignancy in patients presenting 
with HCN.        
 
1.5. Significance of the study 
 
The results of our study will shade a light into how  common is HCCs in our clinical settings 
and will also increase our knowledge on diagnosis and decision making in term of 
management of HCN. 
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CHAPTER TWO 
LITERATURE REVIEW 
 
2.1: INTRODUCTION 
 
Thyroid nodules are common in clinical practice, occurring in 4%–10% of the population [11]. 
More than 60% of thyroid nodules are non-palpable and are detected incidentally during a 
radiologic procedure such as ultrasound (US), computed tomography (CT), or positron 
emission tomography (PET) scanning 
[12, 13][14-18]
. Thyroid nodules come to clinical attention 
when noted by the patient, relatives or a physician during physical examination. Differential 
diagnoses of nodular goiter include multinodular goiter (MNG), chronic lymphocytic 
thyroiditis, thyroid cyst, follicular adenomas (FA), Hurthle cell adenoma (HCA), and thyroid  
cancer 
[1]
.  
Key concern in a patient who has euthyroid nodule is the possibility that the nodule may be 
malignant.  However, only 5-15% of thyroid nodules irrespective of their size are malignant 
[1, 14-21]
. The prevalence of cancer is higher in thyroid nodules in children and individuals who 
are younger than 30 years, adults over 60 years; and if there is history of head and neck 
irradiation. Other patients may have a family history of thyroid cancer 
[14, 15, 22, 23] .
 Common 
cancers of the thyroid are papillary thyroid carcinoma (PTC) and follicular thyroid carcinoma 
(FTC).  
Thyroid neoplasms are increasingly diagnosed nowadays due to widespread availability and 
use of the imaging tools, and perhaps due to environmental and biological factors 
[5]
. They 
are broadly divided into primary and secondary cancers (Table 1) 
[6, 24]
.  Secondary thyroid 
tumors originate from a primary cancer either above (mostly) or below the clavicle. These 
secondary  cancers include breast, renal cell and squamous cell carcinomas 
[25].
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2.2: CLASSIFICATION OF THYROID NEOPLASMS 
 
Primary thyroid tumors are divided into epithelial and non-epithelial tumors. Benign 
epithelial tumors include FA and its oncocytic subtype called HCA. Malignant epithelial 
tumors are however more common and include PTC and FTC, which are more prevalent. The 
other types of primary malignant thyroid tumors are medullary thyroid carcinoma (MTC), 
poorly differentiated thyroid cancer (PDTC), anaplastic thyroid carcinoma (ATC), thyroid 
lymphoma (TL) and metastatic carcinoma 
[18, 21, 26]
. Both poorly differentiated and anaplastic 
thyroid cancers arise from dedifferentiated PTC or FTC 
[24]
. Medullary thyroid carcinoma 
originates from parafollicular cells (C-cells) and may be hereditary or sporadic. Hurthle cell 
carcinoma of the thyroid is a rare cancer of the thyroid. Non-epithelial tumors are extremely 
rare and examples are lymphoma, malignant teratoma and sarcomas.  
According to the World Health Organization (WHO) classification of thyroid neoplasms 
HCA and HCC are considered variants of FA and FTC, respectively 
[2, 8, 20, 27]
. Both HCA and 
HCC show histological characteristics which are similar to what is found in classical 
follicular neoplasms such as follicular growth pattern and encapsulation. Similarly, HCC is 
subcategorized into minimal invasive and widely invasive subtypes like FTC. Their genetic 
basis and clinical behavior are however different. Some authors however consider HCA and 
HCC as separate entities from FA and FTC 
[8].
  
Poorly differentiated thyroid carcinoma is a different type of thyroid cancer 
[6]
. It has various 
subtypes which are categorized based on their growth not on cytological features. The 
consensus diagnostic criteria for poorly differentiated carcinoma have been proposed based 
on the results of an international conference held in Turin, Italy in 2006 
[6]
. When using these 
criteria, these neoplasms fall into a separate intermediate group between well-differentiated 
papillary and follicular carcinomas, and anaplastic carcinoma. Another group of primary 
thyroid neoplasm is the hyalinising trabecular neoplasm which has benign course although its 
share cytologic features similar to that of papillary thyroid carcinomas 
[6]
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Table 1: Histological classifications of thyroid neoplasms 
[6]
 
I. Primary  
  
II. Secondary 
1. Epithelial 2. Non-epithelial  
A. Follicular cell origin Primary lymphoma and 
plasmacytoma 
 
 A.1. Benign 
         - Follicular adenoma 
            a. Conventional type 
            b. Oncocytic Type 
Teratoma   
A.2.Uncertain malignant potential 
       - Hyalinizing trabecular tumor 
Solitary fibrous tumor  
A.3. Malignant 
  - Papillary carcinoma 
  - Follicular carcinoma 
          a. Conventional type 
          b. Oncocytic type 
  -Poorly differentiated carcinoma 
  -Anaplastic  carcinoma 
others  
B. C-cell origin 
     - Medullary carcinoma 
  
C. Mixed follicular and C-cell origin 
    -  Mixed MTC and FTC 
    - Mixed MTC and PTC 
  
 NB: MTC= medullary thyroid carcinoma, PTC= Papillary thyroid carcinoma, FTC= Follicular thyroid 
carcinoma. 
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2.3: EPIDEMIOLOGY 
 
Thyroid malignancies are the most common endocrine cancers and accounts for 3-10% of 
newly diagnosed cancers annually 
[1, 3, 4, 14]
. The incidence varies worldwide depending on 
geographical location, sex, age and ethnicity. High incidence of thyroid cancer is seen in 
South Korea, North America and Australia[6]. Thyroid cancer can occur at any age but is rare 
in children. The average age of patients with thyroid cancer is around 50-60 years. Thyroid 
cancer is three times more common in women than men and in Caucasians than in black 
ethnic group 
[6]
  
The incidence of thyroid carcinoma has been rising especially papillary thyroid carcinoma. It 
is attributed  to two main factors 
[6]
. These are  improvement in detection rate of thyroid 
nodule based on ultrasound followed by  FNAC and  improved understanding of follicular 
variant of papillary thyroid carcinoma which was initially classified as  a follicular thyroid 
carcinoma 
[6]
.  
 
2.4: RISK FACTORS FOR THYROID CANCERS 
 
Risk factors for thyroid neoplasms include genetic and environmental factors. Genetic 
susceptibility is well established in medullary thyroid carcinoma such as in multiple 
endocrine neoplasia (MEN 2a and 2B) 
[6]
. It is also observed in familial adenomatous 
polyposis (FAP) associated papillary thyroid carcinoma (PTC) of the thyroid which is due to 
mutation of adenomatous polyposis coli (APC) gene. Thyroid neoplasms are also seen in 
PTEN gene mutations which lead to susceptibility to follicular neoplasms although papillary 
carcinoma can also occur. Rarely, thyroid neoplasia is seen as part of Carney complex 
components of which include Werner syndrome, Peutz–Jeghers syndrome, and MEN 
syndromes. Family history of thyroid malignancy is another risk factor. Most of these thyroid 
neoplasms are known as familial non-medullary thyroid carcinomas and approximately 90% 
are papillary in nature and occur in first-degree relatives 
[6]
. Few cases of genetically 
predisposed HCC have been reported 
[28]
. 
Environmental factors which may predispose a patient to thyroid cancer include previous 
radiation exposure and iodine status in the region 
[29]
. Head and neck irradiation during early 
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childhood dramatically increases the risk of developing thyroid cancer and the risk of 
developing cancer is dependent on the dose and the time period which has elapsed following 
exposure. The likely cancer which would develop after irradiation damage is papillary 
carcinoma which often is multifocal. However HCC can also occur. 
Both iodine deficient and replete states predispose to thyroid cancer. Follicular carcinoma is 
more prevalent in areas where iodine deficiency is endemic whereas papillary carcinoma 
predominates in iodine supply is sufficient 
[30-32]
. Universal iodine supplementation has led to 
change in the profile of thyroid cancers in low and middle income countries 
[33, 34]
.  As HCC 
is often preceded by Hurthle metaplasia such as in MNG, it is highly probable that iodine 
deficiency would also influence its occurrence.  
 
2.5:  TYPES OF THYROID CANCERS 
 
Common primary thyroid cancers are papillary, follicular including Hurthle cell subtype, 
medullary  and anaplastic thyroid cancers which constitute  approximately 80%, 15%, 3% 
and less than 2%; respectively 
[3]
.  
 
2.5.1: Papillary thyroid carcinoma 
 
Papillary thyroid carcinoma is observed in  iodine-sufficient areas and its main risk factor is 
ionizing irradiation to the head and neck region during childhood. It is a disease of young 
adults as majority of the patients are less than 45 years at presentation. It is indolent tumor 
with very good prognosis despite propensity to metastasize to regional lymph nodes. 
Pathologically it has papillary proliferation with gray to white color on gross examination. 
Microscopically, cells have large nuclei, the so called “Orphan-Annie” eyes and nuclear 
grooving. The cells may also contain psammoma bodies. Many subtypes of papillary 
carcinoma are observed and are thought to play a role in determining aggressiveness of the 
disease. Some of these subtypes of PTC include  follicular, tall cell, Sclerosing and solid 
variants 
[3, 35]
. Hurthle cell papillary thyroid carcinoma has been described and it has both 
cytological features of HCC and PTC 
[36]
. 
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2.5.2: Follicular thyroid carcinoma 
 
Follicular thyroid carcinoma (FTC) represents about 15% of thyroid cancers. It is however 
more common in iodine deficient areas. Pathologically, it usually presents as a solitary 
encapsulated nodule with no papillary proliferation and is gray-tan in color. Follicular thyroid 
carcinoma is seen at average age of 50 years 
[37]
. Confirmation of the diagnosis of FTC 
requires demonstration of capsular invasion, vascular invasion or both; which is not possible 
on FNAC. They are of two types of FTC which are minimally or widely invasive FTC 
[3, 6]
. 
Hurthle cell carcinoma is considered a variant of FTC. Oxyphilic FTC has been described, 
see below 
[26, 37]
.   
 
2.5.3: Poorly differentiated thyroid carcinoma 
 
Poorly differentiated thyroid cancers are different entities and sit between well differentiated 
and undifferentiated cancers of the thyroid gland. They arise as a result of dedifferentiation of 
a longstanding PTC or FTC 
[38-40]
. 
 
2.5.4: Anaplastic thyroid carcinoma 
 
Anaplastic thyroid carcinoma (ATC) is an aggressive undifferentiated cancer mostly due to 
de-differentiation of differentiated follicular and papillary thyroid carcinomas. It consists of 
spindle cells and squamous cells 
[3]
. 
 
2.5.5: Medullary thyroid carcinoma 
 
Medullary thyroid carcinoma (MTC) represents about 3% of thyroid cancers. It is a 
neuroendocrine tumor arising from C-cells which produce calcitonin. There are two types of 
MTCs which are sporadic and syndromic MTCs. Familial MTC accounts for 10-30% of 
MTCs overall and is seen  in MEN 2a, MEN 2b and familial medullary thyroid carcinoma 
(FMTC) 
[3]
. Oxyphilic medullary thyroid carcinoma has been described, see below 
[26, 37]
. 
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2.6: HURTHLE CELL NEOPLASMS 
 
Hurthle cell neoplasms are rare types of thyroid tumors and include non-neoplastic and 
neoplastic HCNs (HCA and HCC) 
[1, 4, 10]
. They make up about 3-10%of all epithelial thyroid 
tumors 
[41]
. According to WHO Classification, HCN is categorized under follicular neoplasms 
and named as oncocytic subtype. However some authors consider it as a separate entity 
[3, 8, 20, 
42, 43]
.  
 
2.6.1: Epidemiology of Hurthle cell neoplasms 
 
Hurthle cell neoplasms (HCN) are encapsulated tumors that consist predominantly or entirely 
of Hurthle cells i.e. more than 50-75% 
[7, 44]
. They are two types: Hurthle cell adenoma 
(HCA) and Hurthle cell carcinoma (HCC). Hurthle cell carcinoma of the thyroid gland 
represents between 5-10% of all differentiated thyroid carcinomas (DTC) [7, 8, 20, 45]. The 
incidence of Hurthle cell carcinoma is varied and estimated between 13-67% 
[1]
. It has no 
racial predilection. The average age range is 50-60 years 10 above that of other epithelial 
cancers. 
 
2.6.2: Pathology of Hurthle cell neoplasms 
 
Hurthle cells in thyroid gland are named as oncocytic cells 
[4]
. When observed without a 
tumor the condition is called oncocytic change, which is a metaplastic condition. The 
metaplasia occurs in chronic thyroiditis, Graves’ disease and multinodular goiter (MNG). If 
the condition is not reversed it may lead to neoplasm known as Hurthle cell neoplasm. 
Hurthle cells are also found in other tissues including salivary glands and the esophagus 
[1, 4, 
46]
. 
Hurthle cell neoplasm is an encapsulated tumor composed of more than 50-75% of Hurthle 
cells with scanty colloid. Diagnosis of HCC cannot be conclusively made on FNAC. 
Differentiating HCA from HCC requires histological confirmation of capsular invasion, 
vascular invasion or both 
[8, 20, 27, 42, 47]
. Histologically HCC is divided into minimally and 
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widely invasive HCC,   as its follicular counterpart. It is classified as  minimally invasive 
subtype when it has less than four (4) foci of capsular or vascular invasion while more than 
four  foci are needed for diagnosis of widely  invasive HCC 
[10]
. Rare variants of HCC 
include Hurthle cell papillary thyroid carcinoma, Hurthle cell follicular carcinoma and 
Hurthle cell medullary carcinoma 
[10]
. 
 
2.6.3: Prognosis of Hurthle cell carcinoma 
 
Hurthle cell carcinoma behaves more aggressively in comparison to other differentiated 
thyroid cancers, especially in elderly patients 
[48]
. It has high likelihood of multi-centricity 
and distant metastasis compared to other DTCs. It has a high metastatic potential in 
comparison to PTC and FTC, which is estimated to be about 10-20% at initial presentation 
[49, 
50]
. Hurthle cell carcinoma is susceptible to metastasize to regional lymph node, about 10% 
unlike the follicular counterpart 
[6, 51]
. Common sites of distant metastasis are bones, brain 
and lungs.  
Hurthle cell carcinoma is less avid and therefore relatively resistant to radioactive iodine 
therapy 
[43]
. Even the papillary thyroid carcinoma and follicular thyroid carcinoma variants of 
HCC are not responsive to 
131
I therapy 
[26, 37]
. The overall mortality of HCC is estimated to be 
between 9-28% 
[50, 52]
.  
 
2.6.4: Risk factors for Hurthle cell carcinoma 
 
Risk factors associated with the development of HCC are generally the same as with other 
differentiated thyroid cancers. Some specific etiological factors are adenoma-carcinoma 
sequence which is not universally accepted, somatic gene mutation, oncogene activation (e.g. 
ras mutation), p53 gene over expression and gene rearrangement (RET/PTC) which is seen in 
Hurthle cell papillary thyroid carcinoma 
[28, 53]
. Other variants of HCC include Hurthle cell 
follicular carcinoma and medullary Hurthle cell carcinoma 
[54]
. Patients who are at risk for 
HCC are of older age, male gender and have tumors which are larger than 4-6cm 
[1, 6, 8, 17, 20, 
42, 46-48, 54-58]
.  
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2.7. DIAGNOSTIC EVALUATION OF THYROID NODULES 
 
2.7.1: Introduction 
 
The initial evaluation of all patients with thyroid nodules whether discovered by a physician 
or incidentally on radiologic procedures (US, CT, MRI or PET) and suspicious for 
malignancy includes clinical assessment, measurement of serum TSH and ultrasound to 
confirm the presence of nodule. Ultrasound also allows for confirmation of whether the 
nodule is cystic or solid and if it solid to check if it has worrisome features  
[55]
. 
 
2.7.2: Clinical evaluation of a patient presenting with thyroid nodule 
 
Although history and examination are not accurate for diagnosis of thyroid cancer, there are 
several factors in history that may suggest an increased likelihood of malignancy 
[1, 15]
. These 
factors include history of head and neck irradiation, painless mass which is rapidly enlarging, 
hoarseness of voice, cervical lymphadenopathy and family history of thyroid cancer 
[14, 15, 22]
. 
Symptoms suggestive of hyperfunction of the thyroid gland such as heat intolerance and 
palpitations are uncommon in  patients who have thyroid cancer 
[59]
. Physical findings of hard 
mass which is fixed, cervical lymphadenopathy, Horner’s syndrome or vocal cord paralysis 
are all suggestive thyroid cancer.  
 
2.7.3: Biochemical evaluation of a patient presenting with thyroid nodule 
 
The initial laboratory investigation to be done in all patients with thyroid nodules is testing 
for serum level of TSH.  Additional laboratory tests such as free thyroxine (T4), free tri-
iodothyronine (T3), thyroglobulin (Tg) and calcitonin level are done selectively 
[14, 18]
. Serum 
TSH above 2.00 mIU/l  is an independent predictive factor for malignancy in a patient who 
has a thyroid nodule 
[60, 61]
. The level of thyroglobulin was found by some authors to be 
independent predictive factor for follicular or Hurthle cell carcinomas 
[62-64]
. Thyroglobulin 
levels have been used for triage in patients having Hurthle cell lesions. 
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2.7.4:  Radiological evaluation of a patient presenting with thyroid nodule  
 
Ultrasound should be done in all patients suspected of solitary or multinodular goiter on 
physical examination or incidentally found on other imagining studies such as CT scan and 
scintigraphy 
[13]
. It is the first-line diagnostic tool to detect and characterizes patient’s thyroid 
nodules following test for TSH level
 [65]
. Ultrasound scan (US) is a quick, inexpensive, 
readily available and non-invasive investigation tool for thyroid nodules 
[42, 66-69]
. If TSH is 
low or subnormal thyroid scintigraphy and/or color-flow Doppler ultrasound are/is added.  
The following are sonographic features which categorize the patients into highly suspicious 
of malignant nodule (hypoechoic mass, micro calcification, central vascularity, irregular 
margins, incomplete halo, nodule taller than wide and larger size) 
[13]
. Thyroid Imaging 
Report and Data System (TIRADS) is a new way to characterize the nodule from benign to 
highly suspicious of malignancy (Table 2) 
[13, 15, 70-72]
. Horvath et al, correlated FNAC of 500 
nodules and following TIRADS categories were established 
[70-72]
: 
 TIRADS 1: Normal thyroid gland 
 TIRADS 2: Benign condition ( 0% malignancy) 
 TIRADS 3: Probably benign ( <5% malignancy) 
 TIRADS 4: Suspicious for malignancy ( 4a 5-10%, 4b 10-80% malignancy) 
 TIRADS 5: Probably malignant 
 TIRADS 6: Biopsy proven malignancy 
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Table 2:  Expanded TIRADS 
[15]
 
Sonographic Pattern US features Malignancy risk % 
High suspicion Solid hypoechoic nodule or 
solid hypoechoic component 
of a partially cystic nodule 
with one or more of the 
following features  
i. Irregular margins 
(infiltrative, micro 
lobulated), 
ii. Micro calcifications,  
iii. Taller than wide shape,  
iv. Rim calcifications with 
small extrusive soft 
tissue component,  
v. Evidence of ETE 
 
70-90% 
Intermediate suspicion Hypoechoic solid nodule with 
smooth margins without micro 
calcifications, ETE, or taller 
than wide shape. 
10-20% 
Low suspicion Isoechoic or hyperechoic solid 
nodule, or partially cystic 
nodule with eccentric solid 
areas, without micro 
calcification, irregular margin 
or ETE, or taller than wide 
shape. 
5-10% 
Very low suspicion Spongiform or partially cystic 
nodules without any of the 
sonographic features described 
<3% 
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in low, intermediate, or high 
suspicion patterns 
Benign Purely cystic nodules (no solid 
component) 
<1% 
NB: ATA 2015= American thyroid association, ETE= extra-thyroidal extension 
 
Ultrasound is not diagnostic for HCC as there are no classical findings. Similar sonographic 
features such solid architecture, hypo- or hetero-echogenicity, micro calcifications, increased 
intra-nodal vascularity and irregular border are found in HCC.  
Ultrasound Elastography (USE)/elastosonography is a new diagnostic modality that assesses 
hardness as an indicator of malignancy in thyroid nodules. It has a high specificity and 
sensitivity independent of the nodule size 
[67]
. It is used for further evaluation of Bethesda III 
and IV lesion (table 3a). There is scarcity of report regarding its role in the diagnostic 
evaluation HCNs. Thyroid scintigraphy has a limited role in evaluation of euthyroid solitary 
nodule, even if it is HCN  
[14]
. 
 
2.7.5: The role of fine needle aspiration cytology in evaluation of HCNs  
 
Fine-needle aspiration cytology is the gold standard in the management of thyroid nodule 
[73, 
74]. Indications for FNAC assessment of thyroid nodule include patients’ risk profile, nodule 
size and sonographic features suspicious for malignancy 
[14, 15]
. FNAC can be done blindly or 
preferably under ultrasound guidance to target the suspicious nodules especially if the nodule 
is less than 2cm in diameter or is posteriorly situated 
[75]
. Tissue samples are obtained by 
using 23-27 gauge needle attached to 10ml syringe. Materials are smeared on slide, fixed 
with alcohol and stained. Fine needle aspiration cytology is deemed adequate if it is 
diagnostic or if the sample contains four to six (4 to 6) groups of well-preserved cells each 
having 10 to 12 follicular cells. It is  sometimes difficult obtain adequate sample from cystic 
nodules 
[76]
.   
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Fine-needle aspiration cytology is a simple and safe procedure that has reduced the number of 
patients undergoing unnecessary thyroidectomy. Pain and hematomas are common but minor 
complications following FNAC procedure. Tracheal puncture, needle track seeding by 
malignant cells and recurrent laryngeal nerve injury are rare.  
In experienced hands adequate sampling is obtained in 90.0 to 97.0% of thyroid nodules 
[47, 55, 
75, 77]. 
The overall accuracy of FNAC exceeds 95.0% 
[20]
. Sensitivity and specificity of thyroid 
FNAC for the diagnosis of malignancy are 94.0% and 98.5%, respectively 
[78]
. Recently, 
published international guidelines report the average sensitivity and specificity for thyroid 
FNAC of 83.0% and 92.0% respectively and the accuracy of 84.0-95.0% for PTC, MTC, and 
lymphoma 
[79]
. However, these sensitivity and specificity data are not applicable to FCNs and 
HCNs 85-90.0% 
[20, 77, 78, 80]
. 
For interpretation of thyroid FNAC result, The Bethesda System for Reporting Thyroid 
Cytopathology (Bethesda System) is currently preferred 
[81]
. The Bethesda System places 
thyroid FNAC results into six diagnostic categories. Please see Table 3a and 3b for diagnostic 
categories and recommended management 
[20]
. 
 
Table 3a: The Bethesda System for Reporting Thyroid Cytopathology: Recommended 
Diagnostic Categories 
[20]
 
I. Non-diagnostic or Unsatisfactory 
    Cyst fluid only 
    Virtually acellular specimen 
    Other (obscuring blood, clotting artifact, etc.) 
II. Benign 
  Consistent with a benign follicular nodule (includes adenomatous nodule, colloid nodule, 
etc.) 
  Consistent with lymphocytic (Hashimoto) thyroiditis in the proper clinical context 
  Consistent with granulomatous (subacute) thyroiditis 
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  Other 
III. Atypia of Undetermined Significance or Follicular Lesion of Undetermined 
Significance 
IV. Follicular Neoplasm or Suspicious for a Follicular Neoplasm 
    Specify if Hurthle cell (oncocytic) type 
V. Suspicious for Malignancy 
     Suspicious for papillary carcinoma 
     Suspicious for medullary carcinoma 
Suspicious for metastatic carcinoma 
     Suspicious for lymphoma 
     Other 
VI. Malignant 
     Papillary thyroid carcinoma (PTC) 
     Poorly differentiated carcinoma 
    Medullary thyroid carcinoma (MTC) 
    Undifferentiated (anaplastic) carcinoma 
    Squamous cell carcinoma 
    Carcinoma with mixed features (specify) 
    Metastatic carcinoma 
    Non-Hodgkin lymphoma 
    Other 
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Table 3b: The Bethesda System for Reporting Thyroid Cytopathology: Implied Risk of 
Malignancy and Recommended Clinical Management 
[20]
Diagnostic category              Risk of malignancy 
(%)             
   Recommended management 
Non-diagnostic or 
unsatisfactory        
         1-4                             Repeat FNA with ultrasound   
guidance 
Benign            0-3                             Clinical follow-up 
 
AUS or FLUS                                      ~5-15                        Repeat FNA 
Suspicious for follicular 
neoplasm 
       15-30                    surgical lobectomy 
Suspicious for malignancy       60-75       Near-total thyroidectomy or    
surgical lobectomy 
Malignant       >95   Near-total thyroidectomy or   
surgical lobectomy 
NB: AUS= Atypia of unknown significance, FLUS= follicular lesion of unknown significance  
 
There is uncertainty in thyroid cytology because of the category of follicular neoplasm as it 
cannot differentiate between adenoma from carcinoma. Bethesda I and Bethesda III add to 
this uncertainty 
[20, 46, 82, 83]
. These indeterminate groups constitute around 10% of all FNAC 
results 
[58, 84]
.  Molecular markers including Ki67 index and mutational analysis are used to 
assist to either rule-in or rule out malignancy when FNAC is inconclusive 
[74]
. The mutational 
analyses include three tests; Gene Expression Classifier (GEC)[85], 7-gene panel of genetic 
mutation and rearrangement testing[86] and multiplexed next-generation sequencing 
[15]
 
(NGS) panel 
[10]
  None however has been found to be reliable for diagnosis of HCC.  
Non-diagnostic FNAC (Bethesda I) smears occur when there are insufficient follicular cells 
to make a cytological diagnosis which happens in 5-10% of FNACs and malignant risk is 
about 1-4% 
[14, 15]
. A repeat FNAC under ultrasound guidance is indicated unless two or more 
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FNACs have been done and are non-diagnostic as the patient has to be taken for biopsy 
which entails as minimum lobectomy of the index side 
[58]
. Diagnostic total thyroidectomy is 
sometimes indicated in high risk patients such as patients with strong family history, previous 
neck irradiation, multi-nodularity, bilateral nodules and if the thyroid nodule is greater than 
4cm in diameter 
[42, 87]
. Hurthle cell neoplasm is unlikely to fall under this category.  
Fine needle aspiration cytology yields benign diagnosis (Bethesda II) in 60-70% of cases. 
Some of these benign conditions include  colloid goiter, adenomatous nodule and 
hyperplastic nodules 
[15, 20]
. The risk of malignancy in Bethesda II lesion is about 0-4% 
[20]
. 
These patients should be followed up with sonar and physical exam six monthly and 
thereafter yearly depending on risk profile. A large benign nodule may necessitate 
thyroidectomy if it is causing pressure symptoms or for cosmetic reasons. Hurthle cells are 
not a rare finding in benign conditions such MNG and chronic thyroiditis. Despite a benign 
report management of these patients should be guided by clinical risk profile. 
Atypia of undetermined significance (Bethesda III) accounts for 3-6% of thyroid FNAC 
results and has a malignant risk ranging from 5-15%. A repeat FNAC is therefore warranted 
[20, 77]. Diagnostic lobectomy may be indicated based on patient’s risk profile namely clinical 
risk, and radiologic features 
[15]
. Some HCNs will fall into this group. 
As FNAC cannot discriminate between follicular adenoma and carcinoma, the term 
“follicular neoplasm” (FN) is used.  Approximately 15-30% FNs will turn out to be 
malignant on subsequent lobectomy 
[12, 58, 77, 78, 83]
. Hurthle cell adenoma and carcinoma are 
oncocytic variants of follicular adenoma (FA) and follicular carcinoma (FC), respectively. 
Cellular samples made almost exclusively of Hurthle cells are called HCN rather than FN. 
About 16-25% will be proven to be non-neoplastic proliferation of Hurthle cells known as 
Hurthle cell change. Nearly 15% to 45% of nodules will be proven to be malignant and the 
remainders will be HCA 
[17, 20, 88]
. This designated class required diagnostic lobectomy and 
isthmusectomy of the involved side. Total thyroidectomy is performed occasionally for high 
risk lesion 
[42, 87]
. 
Majority of thyroid cancers are diagnosed with certainty on FNAC. It however is not the case 
with follicular variant of PTC. Fine needle aspiration cytology result may return ‘suspicious 
for malignancy’ or specifically suspicious for papillary carcinoma (Bethesda V). The rate of 
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malignancy in Bethesda V lesion is 60-75% 
[20]
. These patients are managed with total 
thyroidectomy. Bethesda V finding is less likely in HCN. 
In about 3-7% of FNAs, FNAC yield a papillary thyroid cancer (PTC) and occasionally 
medullary (MTC) or anaplastic cancer (Bethesda VI). These patients should undergo total 
thyroidectomy with or without lymph node dissection 
[20]
. As HCC cannot be diagnosed on 
FNAC it is highly unlikely that any of HCN tumors return a Bethesda VI report.  
 
2.8: STAGING OF HURTHLE CELL CARCINOMA 
 
Various prognostic factors and staging systems are used in the management of DTC and HCC 
[4, 19, 20, 43, 45, 46, 57, 58, 89, 90]
. These include the tumor, node and metastasis (TNM) system of 
AJCC (Table 4).  
Table 4: Tumor-Node-Metastasis staging system of differentiated thyroid carcinoma 
[15, 91, 92]
 
Stage  Age <45 Age >45 
   
1 Any T, any N, M0 T1, N0, M0 
2 Any T, Any N, M1 T2 or T3, N0, M0 
3  T4 or N1, M0 
4  Any T, any N, M1 
 Tumor staging:                Nodal status                         Metastasis 
T1 < 1cm                               N0= no nodal metastasis    M0= no metastasis 
T2 > cm < 4cm                      N1= nodal metastasis          M1= Metastasis 
T3 > 4cm 
T4 beyond thyroid  
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The TNM staging system is most (NCCN and AJCC 7
th
 Edition (2010) accepted system 
worldwide. Clinicopathological factors which are used for TNM system are age of patient, 
gender of the patient, size of tumor, metastasis and presence or absence of extra-thyroidal 
extension. The other prognosticating scoring systems are  AGES (for age, grade, extent and 
size), AMES (for  age, metastasis, extent and size) and MACIS (for metastasis, age, complete 
excision, extra-thyroidal extension and size 
[93]
. 
 
2.9: MANAGEMENT OF HURTHLE CELL NEOPLASMS  
 
Treatment of differentiated thyroid carcinomas includes surgery, TSH suppression, 
chemotherapy and radioactive iodine treatments 
[94]
. Surgery is the mainstay of treatment for 
patients with DTCs 
[15, 21]
.  Based on risk profile, patients may undergo either thyroid 
lobectomy, total thyroidectomy alone, or total thyroidectomy and lymph node dissection. 
TSH suppression and Iodine 131 (
131
I) 
 
ablation are added in patients who have intermediate 
and high risk DTC 
[15]
.  
Diagnostic lobectomy is indicated in the low risk patient while total thyroidectomy is 
preferred for intermediate and high risk patients. Subsequently, TSH suppression with 
thyroxine, radioiodine therapy and adjuvant external beam radiotherapy are added. Thyroid 
hormone (either T4 or T3) is added Thyroxine  to prevent hypothyroidism and to decrease 
TSH, which if it rises may stimulate growth of residual thyroid tissue including metastasis 
[10, 
95]
. The level TSH suppression depends on ATA 2015 risk stratification, and ranges from 
0.5mU/L for low risk patients to <0.1 mU/L in high risk patients 
[15]
. Bone lost, atrial 
fibrillation and cardiac dysfunction are some of toxic effects of thyroxine therapy. The level 
of TSH suppression is therefore tailored based on patient’s risk profile [96, 97]. 
Radioactive iodine is used to ablate residual thyroid tissue and cancer, deposit in the tumor 
bed and metastasis in DTCs. However HCC generally has low uptake of radioactive iodine. 
Addition of radioactive iodine therapy (RAT) is also subject to risk stratifying patients. 
Adjuvant chemotherapy for DTCs include cytotoxic chemotherapy such as doxorubicin; 
kinase inhibitors e.g.  sorafenib and BRAF inhibitor like vemurafenib 
[15]
.  
The accepted surgical approach for a patient suspected to be having HCC is diagnostic 
lobectomy and isthmusectomy except if the patient has high risk  clinical features such as 
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previous neck irradiation, multiple foci and family history of thyroid cancer or the tumor is 
larger than 4cm in diameter 
[10]
. If histology confirms HCC, then completion thyroidectomy 
is considered based on risk profile.  If histology showed a minimally invasive tumor with size 
less than 1 cm in diameter, completion thyroidectomy is not indicated. Widely invasive HCC 
is managed based on ATA risk stratification profile and total thyroidectomy is mandated 
[68]
.  
 
2.10. FOLLOW UP OF PATIENTS WHO HAVE HURTHLE CELL NEOPLASM 
 
Post-surgical treatment of patients with DTC includes scheduled follow up to monitor 
response to treatment as well as detection of recurrence. In the first year neck ultrasound, 
serum TSH and thyroglobulin levels are measured during each visit, 3-6 months 
[15]
.  
Subsequent imaging modalities are required based on risk profile and level of Tg and TSH 
[15, 
98]
. These procedures include FDG-PET scan, magnetic resonance imaging (MRI) and CT 
scan. Clinical outcome is classified based on former tools into one of the following 
categories: 
i. Excellent response: no clinical, radiological and biochemical evidence of disease. 
ii. Biochemical incomplete response: only abnormal Tg or Tg antibodies. 
iii. Structural incomplete response: persistent or new loco-regional or distant metastasis. 
iv. Indeterminate response: nonspecific biochemical and structural findings 
[72]
. 
Subsequently patients are screened in annually basis using the same above mentioned 
parameters. Follow-up of patients following thyroidectomy for HCC is similar.  
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CHAPTER THREE 
RESEARCH METHODOLOGY 
 
3.1: INTRODUCTION 
 
Hurthle cell neoplasm is a variant of follicular thyroid neoplasms 
[99]
. Distinction between 
HCA and HCC remains a challenge 
[87]
. No single preoperative diagnostic test is able to 
demonstrate this distinction, however molecular study is promising. After literature search, 
there is no reported incidence of this type of cancer has been conducted in this province. We 
retrospectively search for demographic factors and histopathological features which can be 
used to predict of HCC in patients with HCN.  
 
3.2: STUDY AIM AND OBJECTIVES 
 
3.2.1: Study aim 
 
To determine the prevalence of HCC and its demographic factors and histopathological 
features that can be used to predict the risk of malignancy in HCN.   
 
3.2.2: Study objectives 
 
i. To determine the demographic and histopathological findings in patients who had Hurthle 
cell neoplasms. 
ii. To determine what proportion of patients who had thyroidectomy for Hurthle cell 
neoplasm were on histology confirmed to be having Hurthle cell carcinoma. 
iii. To determine if fine needle aspiration cytology is able to distinguish Hurthle cell adenoma 
from Hurthle cell carcinoma. 
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iv. To determine if there are factors which are predictive of HCC in patients presenting with 
Hurthle cell neoplasms.        
 
3.3: Methodology 
 
3.3.1: Research design 
 
Audit based on histopathology results of the National Health Laboratory Services (NHLS), 
Department of Anatomical Pathology. 
 
3.3.2: Setting 
 
Three academic hospitals of Johannesburg, South Africa namely: Chris Hani Baragwanath 
Academic Hospital (CHBAH), Helen Joseph Hospital (HJH), Charlotte Maxeke 
Johannesburg Academic Hospital and the Department of Anatomical Pathology of the NHLS. 
i. Chris Hani Baragwanath Hospital (CHBAH) is a public hospital located in 
southern part of Gauteng (Soweto), Johannesburg, South Africa.  
ii. Helen Joseph Hospital (HJH)   is a public hospital located in Auckland Park, 
Johannesburg, South Africa.  
iii. Charlotte Maxeke Academic Hospital (CMJAH) is a public hospital located in 
Parktown, Johannesburg, South Africa.                           
 
3.3.3: Study population 
 
Histopathology and FNAC results of all consecutive patients, who underwent thyroidectomy 
in the University hospital between January 2001 and October 2015.  
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3.3.4: Inclusion criteria 
 
1. Histopathology reports of all patients who had thyroidectomy 
2. All available FNA results 
3. All ages 
 
3.3.5: Exclusion Criteria 
 
Thyroidectomy results for benign diseases. 
 
3.3.6: Ethics and Permission 
 
Ethical approval was obtained from the Human Research Ethics Committee of the University 
of the Witwatersrand (Clearance No. M150944). Permission to carry out the study was 
obtained from Department of Anatomical Pathology of NHLS and Research Review Boards 
of respective hospitals. All study participants were given a study number to ensure anonymity 
of data. 
 
3.3.7: Data collection and Statistical Analysis 
 
Demographic and histopathological characteristics data were captured using Excel 
spreadsheet and analyzed using Statistics/Data Analysis software 2015 (version 13.1). 
Continuous data for age and tumor size were presented as mean +/- standard deviation. 
Fisher’s exact test was used for categorical data. Parameters data were compared using 
student’s t-test. The level of significance was set at P-value of less 0.05.   
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CHAPTER FOUR 
4.1: RESULTS 
 
A total of 2641 histopathological reports of consecutive patients who underwent 
thyroidectomy were found and majority was for benign disease 74.4% (1965/2641) (Figure 
1a and 1b) and were excluded.   
 
Figure 1a: Breakdown of histology results of thyroidectomy specimens 
Reports reviewed  (N=2641) 
Reports included(n=676) 
Benign tumours (n=195) 
Follicular Adenoma(n=115) 
Hurthle cell adenoma(n=80) 
malignant tumours(n=481) 
PTC  (n=298) 
FTC (n=82) 
MTC (n=40) 
HCC (n=27) 
Anaplastic (n=15) 
Rare Malignancies (n=2) 
Metastatic (n=8) 
Unspecified (n=3) 
Lymphoma (n=6) 
Excluded reports (n=1965) 
Benign lesions 
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Figure 1b: Abbreviated breakdown of histology results of thyroidectomies. 
 
4.2: Neoplasms of thyroid gland 
 
25.6% (676/2641) of thyroidectomies were for benign and malignant tumours (Table 5 and 
Figure 1a and 1b). The mean age of patients who had thyroidectomy for tumours in years was 
47.3 +/- 15.9 (SD) and 82.5% (558/676) were females. However 71.2% (481/676) were 
malignant of which 62.0% (298/481) were papillary and 5.6% (27/481) Hurthle cell 
carcinomas (Table 5).   
 
 
 
 
 
Total 
patients 
reviewed 
( N=2641) 
Excluded 
(n=1965) 
benign 
lesions 
Included (n=676) 
tumours 
HCN 
(n=107) 
HCC 
(n=27) 
HCA 
(n=80) 
other thyroid 
tumours (n=569) 
Benign 
(n=115) Malignant 
(n=454) 
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Table 5: Distribution of thyroid tumors according to histology reports. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Pathological diagnosis n=676  Percent  
Benign tumors (n=195)     
Follicular adenoma  115  59.0%  
Hurthle cell adenoma  80  41.0%  
malignant tumors (n=481)      
Papillary carcinoma  298  62.0%  
Follicular carcinoma  82  17%  
Medullary carcinoma  40  8.3%  
Hurthle cell carcinoma  27  5.6%  
Anaplastic carcinoma  15  3.1%  
Lymphoma  6  1.3%  
Metastatic carcinoma  8  1.7%  
unspecified carcinoma  3  0.6%  
Malignant teratoma of thyroid  1  0.2%  
Malignant solitary fibrous tumor  1  0.2%  
29 
 
 
Figure 2: Breakdown of thyroid tumors of the thyroid based on histology reports. NB: 
others= malignant teratoma and malignant solitary fibrous carcinoma of the thyroid 
 
4.3: Demographic of patients with Hurthle cell neoplasms 
 
A total of 107 patients had HCN of which 75.0% (80/107) were HCA and 25.0% were HCC. 
The majority of patients with HCA were females (86.0%). Patients with HCC included 21 
females and six (6) males with a female to male ratio of 4.5:1 and a mean age of 55.0 years 
(32-84). Patients with HCA were 71 females and nine males (at ratio of 8.9:1) with a mean 
age of 52.3 years (23-95) (Figure 3 and 4). The difference of age and gender were not 
statistically significant between two groups (P=0.156), (Table 6). Around 86.o% of the study 
cohort were females. Nonetheless, the malignancy rate was 22.8% in females compare to 
40% in males who had HCN.                                                                                                                                                                                                                           
 
 
62% 
17% 
8.3% 
5.6% 
3.1% 4% 
481 patients with malignant thyroid 
cancers 
Papillary
carcinoma
Follicular
carcinoma
Medullary
carcinoma
Hurthle cell
carcinoma
Anaplatic
carcinoma
Others
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Figure 3: Mean age of 107 HCN patients. 
 
Figure 4: Gender of 107 HCN patients. 
 
80 
27 
52.3 55.0 
HCA HCC
Number Mean age
107 patients over 15 years age range ( HCA= 23-95) & 
 (HCC=32-84)  
Age 
HCA HCC TOTAL
9 6 
15 
71 
21 
92 
Male Female
107 patients by gender  
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Table 6: Characteristics of 107 patients with Hurthle cell tumors 
Parameter Hurthle cell carcinoma Hurthle cell adenoma P value 
No. of patients 27 80  
Male 
Female  
ratio (M/F)                                                    
6 (22.2%) 
21 (77.8%) 
1.0: 4.5
9 (11.3%) 
71 (88.7%) 
1.0: 8.9 
 
 
0.156 
Patient’s age (years)     
<45 7 (26%) 29 (36.3%) NS 
45-65  13 (48%) 31 (38.8%) NS 
>65 6 (22%) 19 (24.9% NS 
Age (yrs.), mean +/- SD 55.0 +/15.0years 52.3+/15.6 years 0.274 
        Range 32-84 23-95  
Tumor size, mean (cm) +/-SD  4.9 +/- 2.7 3.5+/- 2.0 0.016 
    Range (cm) 0.8-10.0 0.2-9.0  
   <1.0 cm 3/26 (11.1%)  NS 
    1-4.0  cm 9/26 (33.3%) 34/52 (65.4% NS 
    >4.0 cm  14/26 (52.8) 18/52 (34.6%) NS 
 
4.4: Diagnosis of HCN 
 
Of 107 patients, 58 had preoperative FNAC results (Table 7).  Of these, 36 FNACs were 
Bethesda III and IV (Table 7) and (Figure 5) and 27.8% (10/36) of the indeterminate FNACs 
were proven to be malignant on Histology. 
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Table 7: FNAC category and Hurthle cell neoplasms 
FNA Category  HCC HCA total 
Malignant 0 7 7 
Benign 1 7 8 
AUS 1 4 5 
FN or FLUS 9 22 31 
Suspicious of Malignant 1 0 1 
Nondiagnostic 1 5 6 
Total 13 45 58 
HCC= Hurthle cell carcinoma, HCA= Hurthle cell adenoma, AUS= Atypia of undetermined 
significance, FN= Follicular neoplasm, FLUS= follicular lesion of undetermined significance 
 
 
Figure 5: Sensitivity and specificity of FNAC to diagnose HCC. 
 
 
FNA
39% 
61% 
Sensitivity
Specificity
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Sensitivity and specificity of FNAC for diagnosis HCC was 39% and 61% sensitivity and 
specificity for HCC, respectively (Tables 8, Figure 5). 
Table 8: Fine-needle aspiration cytology and histology results of 107 Hurthle cell tumors 
 Final Histology 
FNA HCC                        HCA 
FNA        27                              80 
Not available  = 14 v 35 14/27 (51.9%)     35/80 (43.8%) 
Available =13 v 45 13/27 (48.1%)    45/80 (56.2%) 
False negative FNA= 1 1/13                     
True positive =0 0/13                        
 
4.5: Presence and Absence of malignancy 
 
Statistical analysis showed a significant statistical difference between the tumour size of 
HCA and HCC. Malignancy was associated with bigger size (4.9 v 3.5; p= 0.016 (Figure 6). 
Of 27 patients with HCC, 18 were follicular variant HCC, three were papillary variant HCCs 
and the rest were classical HCCs.  
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Figure 6: Tumour size (cm) and risk of malignancy (%). 
 
Patients Management 
 
Close to 41% (44/107) of patients underwent total thyroidectomy and 50.5% (54/107) had 
thyroid lobectomy. Most of the operations were done for multinodular goitre (MNG). Of 27 
patients with HCC; 22.2% (6/27) had total thyroidectomy for MNG in which HHCC was 
incidentally discovered on final histopathology and 48.1% (13/27) had lobectomy and 
isthmusectomy indicated for MNG (Table 8). Total thyroidectomy was done in 33 of the 80 
HCA due to MNG, (Table 9). 
Table 9: Surgical procedures for Hurthle cell neoplasms. 
Operative procedures HCA HCC Total 
Total Thyroidectomy 33 11 44 
Hemithyroidectomy 41 13 54 
Subtotal Thyroidectomy 3 2 5 
Completion Thyroidectomy 2 1 3 
All 79 27 106 
 
1 cm or less 1-4cm >4cm
11.5% 
34.7% 
53.8% 
M
al
ig
n
an
cy
 r
is
k 
Tumour size 
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Table 10: Findings in HCC patients treated with lobectomy (n=13) 
Parameter Age 
(yrs.) 
Gender 
(M/F) 
Maximum 
diameter 
C I (+/-
) 
VI (+/-) Variant 
Case 1  38 F 3.0cm + + Follicular variant HCC 
Case 2 
42 
F 
8.5cm + + Classical HCC 
Case 3 
46 
F 
6.2cm + - Follicular variant HCC 
Case 4 
49 
M 
4.5cm + + Follicular variant HCC 
Case 5 
50 
F 
1.5cm + + Classical HCC  
Case 6 
51 
F 
7.5cm + - Follicular variant HCC 
Case 7 
51 
F 4.0cm 
+ - Follicular variant HCC 
Case 8 57 F 6.0cm 
+ + Papillary variant HCC 
Case 9 58 M 6.0cm 
+ + Follicular variant HCC 
Case 10 63 F 2.5cm 
+ + Classical HCC 
Case 11 79 F 
2.4cm + - Papillary variant HCC 
Case 12 
82 
F 
3.5cm + - Classical HCC 
Case 13 
84 
F 
2.0cm + + Follicular variant HCC 
NB. CI= capsular invasion, VI= vascular invasion 
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CHAPTER FOUR 
 
DISCUSSION 
 
Majority of thyroidectomies 74.4% (1965/2641) were due to benign thyroid diseases. Only 
25.6% (676/2641) of thyroidectomies were done for thyroid tumors in which 71.2% 
(481/676) were malignant neoplasms. Papillary carcinoma was the more common carcinoma 
with 62% (298/481) followed by FTC 17% (82/481). In our study, the prevalence of PTC was 
lower than it has been reported in the literature. The explanation may be due to the fact that in 
the past follicular variant of PTC were classified as follicular neoplasms/carcinoma 
[6]
. 
The incidence of HCN ranges from 3-10% of differentiated thyroid tumors 
[8, 42, 45, 49, 68, 100, 
101]
. Many studies have shown that the prevalence of malignant HCN ranges from 5-35% 
[37, 
42, 45, 57, 68, 101]
 and benign HCN to be 80% or more especially, when found on the background 
of MNG and lymphocytic thyroiditis 
[101]
. In our study Hurthle cell carcinoma represented 
5.6% of all differentiated thyroid carcinomas treated during the study period. The prevalence 
of malignancy among HCNs was 25.2% (27/107) which is the same as what have been 
reported in the literature 
[37, 42, 101]
.  
The diagnosis of Hurthle cell carcinoma is made on the demonstration of capsular and/or 
vascular invasion which can be either minimally or widely invasion on histology.  In our 
study, of the 27 patients with HCC, all had capsular invasion whereas 16 of these had both 
capsular and vascular invasion 
[62, 102]
. Several studies have shown that FNAC is a reliable 
test to diagnose HCNs 
[8, 20, 37, 50]
. However, the distinction between benign and malignant 
HCN pre-operatively is not possible 
[8, 13, 37, 42, 62, 100]
.  This differentiation is so critical 
because definitive surgery, such as total thyroidectomy can be done for carcinoma upfront 
[43, 
58, 101]
, and thyroid lobectomy reserved for HCA 
[4, 19, 26, 42, 44, 45, 62, 66, 100, 103-105]
.  Appropriate 
surgical treatment is important as HCC is relatively resistant to RAI ablative therapy 
[42, 57, 
106]
.  Some experts recommend total thyroidectomy for HCN based on evidence that suggest 
that HCC is an aggressive tumor with high  metastasis potential, limited RAI uptake and an 
overall poor prognosis 
[3, 20, 107]
.   
Of 58 patients with adequate FNAC, 37 were suspicious of HCN of which 11 were 
histologically confirmed HCC comprising of about 29.7%. Similar results were reported by 
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Chen et al, that 20-30% of Bethesda III and IV FNAC will turn up to be malignant on final 
histology 
[42]
 . 
Many Hurthle cell neoplasms, many clinicohistopathological features which are predictive 
for malignancy have been studied; these include patient’s age, gender, and tumor size [2, 4, 8, 19, 
26, 42, 43, 45, 46, 57, 58, 67, 68, 82]
.  Patients with HCC are older than HCA counterpart as reported by 
Carcangiu et al 
[2]
 and Lopez-Penabad et al 
[56, 57]
. In this study, none of the clinical factors 
found to be statistically significant.  Hurthle cell neoplasm patients with HCC diagnosed on 
final histopathology, compared with patients with benign pathology were of similar age 
(mean age 55.0+/- 15 vs. 52.3) 
[58]
.  Distribution by gender was also not statistically 
significant between these two groups. Many investigators have reported that the size of tumor 
increase the likelihood of HCC among patients with HCN 
[2, 4, 42, 46, 108]
. Straziser et al 
reported that the malignancy rate in patients with tumor size between 1cm and 4cm and 
greater than 4cm were 20% and 40%, respectively 
[4]
. Chen et al also reported that tumor 
which is 1cm or less has 17% malignancy risk compared to 23% and 65% HCN with tumor 
size of 1-4cm and > 4cm, respectively 
[42]
. Discordant results were observed in our study. 
Malignancy rate was 46% and 53% for tumor < 4 cm and > 4 cm, respectively. In this report, 
tumor size was predictive for HCC as illustrated by both univariate and multivariate analysis. 
Many authors cited the unpredictability of the behavior of HCC in keeping with the variation 
in aggressiveness related to its variants 
[7, 8]
.  
There are three variants of HCC; papillary variant of HCC, Hurthle cell follicular variant and 
oncocytic variant of medullary carcinoma 
[109]
. HCPTC is composed of cells with typical 
nuclear features of PTC as well as with features of oncocytic lesions (granular cytoplasm 
with >75% of oncocytic cells) 
[110]
. HCPTC is common in the fifth decade, with 10-15% 
nodal involvement unlike classical HCC (<5% nodal involvement) and poor prognosis as 
well as insensitivity to RAI. Unlike HCC, oncocytic variant PTC do show RET/PTC gene 
rearrangement. Hurthle cell follicular variant is identical to classical HCC in term of age, 
aggressive behavior, hematogenously spread and insensitivity to RAI except on morphology 
where HCC has cells which are polygonal, large with granular cytoplasm and scanty colloid. 
Oncocytic variant of medullary carcinoma is not truly a variant of HCC although it is 
composed of some oncocytic cells which have very small nuclei unlike pleomorphic nuclei of 
HCC 
[50, 51]
.   
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Management of HCNs is not standardized due to the controversies regarding the diagnosis 
and the biological behavior. Some investigators recommended thyroid lobectomy as an initial 
surgical procedure, followed by completion thyroidectomy upon histological diagnosis of 
HCC 
[13, 42]
. Others suggest total thyroidectomy because of the unpredictable behavior 
[42]
, 
multifocality 
[43]
, and high prevalence of the malignancy 
[4, 42, 43, 45]
.     
Regarding initial management of our patients, majority underwent either total 
thyroidectomies (44/107) or thyroid lobectomy/isthmusectomy (54/107) mainly on the 
background of MNG, and incidentally found to be harboring HCC. It is worth mentioning 
that 48.0 % of patients with HCC were managed with thyroid lobectomy only.  
 
Limitations 
 
Like any other retrospective study, our study has many limitations. Our study is the audit of 
histopathological report only. Therefore, the subsequent management for HCC in term of 
completion thyroidectomy and RAI ablation therapy were not looked into. Also long term 
follow-up of patients with HCC was not apparent in order to assess the biological aggressive 
in term of survival and recurrence. Also most of the FNA results were not available for 
review. 
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CHAPTER FIVE 
 
CONCLUSION 
 
Majority of HCCs are diagnosed following thyroidectomy for benign disease.  About a 
quarter of HCNs are malignant and the risk of malignancy increases with size. Age and 
gender are not useful to predict malignancy in HCNs.  
Malignant thyroid neoplasms were accounting 71.2% of all epithelial and non-epithelial 
neoplasms. 62% were papillary thyroid carcinoma, the percentage which is lower than 
described in the literature. This may be attributed to the fact, in the past follicular variant of 
papillary thyroid carcinoma were categorized as follicular carcinoma. 
In our local settings, HCC is not uncommon in comparison to outside world. It has the 
incidence of 5.6% among differentiated thyroid cancers and prevalence of 25.2% among 
HCNs. 86% of study cohort were females and the malignancy risk among female was 22.8% 
comparable to 40% in male. Therefore, thyroid disease is common in female but when 
nodules are found in male chances of being malignant is high. This was not demonstrated by 
statistical analysis as a significant factor in this report. Other independent risk factors 
associated with malignant HCN are older age, and large tumor size. The average age for 
benign versus malignant HCN were relatively similar (52.3 v 55). Tumor size was larger for 
HCC versus HCA (4.9 v 3.5). Total thyroidectomy and thyroid lobectomy/isthmusectomy 
were complimentarily done for our patients, mainly due to MNG and HCN were incidentally 
found. Interestingly, 13/27 of patients HCC were managed only with thyroid lobectomy. 
Regarding variant of HCC, 77.8% (21/27) were both Hurthle cell follicular 85.7% (18/21) 
and Hurthle cell papillary carcinoma 14.3% (3/21). These variants are associated with worst 
prognosis unlike classical HCC. 
Our data showed that the size of the Hurthle cell neoplasm is the only predictive 
clinicopathological factor associated with risk of malignancy. Hence, Hurthle cell neoplasm 
with large size on solitary nodule or on background of multinodular goiter suspected on 
preoperative FNAC should undergo total thyroidectomy, because of higher probability of 
malignancy.  
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Recommendation 
 
We recommend total thyroidectomy thyroid nodule greater than 4cm in diameter if FNAC 
result is suggestive of HCN as the risk of malignancy is above 50%. 
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